The Practitioner's Guide to How Can I Lower Lp(a)?

The Practitioner's Guide to How Can I Lower Lp(a)?

If you've just received a blood panel showing elevated Lp(a), your first instinct might be to reach for a statin. Unfortunately, that's the wrong tool for this particular job. Lipoprotein(a) — often written Lp(a) — is a genetically determined particle that standard cholesterol-lowering drugs largely ignore. Yet elevated Lp(a) (generally defined as ≥ 50 mg/dL or ≥ 125 nmol/L) is associated with a two- to threefold increase in coronary artery disease risk, independent of LDL cholesterol (Kamstrup et al., JAMA 2009; PMID: 19258535).

The question "how can I lower Lp(a)?" is one of the most common things cardiologists hear from patients who've done thorough lab work — and the answer is more nuanced than a single supplement or drug. This guide breaks down the biology, what actually works, what doesn't, and which inflammatory biomarkers to track alongside your Lp(a) to get the full cardiovascular picture.

---

What Is Lp(a) and Why Is It So Hard to Lower?

Lp(a) is a low-density lipoprotein particle with an extra protein called apolipoprotein(a) — apo(a) — covalently bonded to its apoB-100 core. This structure makes it uniquely atherogenic: it promotes clot formation, impairs fibrinolysis, carries oxidized phospholipids into artery walls, and drives plaque inflammation (Tsimikas et al., JACC 2020; PMID: 31948651).

About 70–90% of your Lp(a) level is genetically determined by the LPA gene, which encodes apo(a). This is why most lifestyle interventions produce only modest reductions — you can't opt out of your genome. That said, "modest" reductions still matter, and controlling the inflammatory environment around Lp(a) may be just as important as the number itself.

Standard treatments that do NOT meaningfully lower Lp(a):

• Statins (may actually increase Lp(a) slightly in some individuals)
• Ezetimibe
• Fibrates
• Dietary fat reduction alone

Approaches with at least modest evidence:

• Niacin (extended-release)
• PCSK9 inhibitors (evolocumab, alirocumab) — 20–30% reduction
• RNA-targeted therapies (pelacarsen, olpasiran) — investigational, 65–90% reduction in trials
• Aspirin — does not lower Lp(a) but may blunt its pro-thrombotic effects
• Omega-3 fatty acids — modest, dose-dependent reductions in some populations
• Lipoprotein apheresis — reserved for very high-risk patients

---

How Fast Can I Lower Lp(a)?

This is one of the most searched questions by patients newly diagnosed with elevated Lp(a) — and the timeline expectations matter for adherence.

Because Lp(a) is largely genetically set, dramatic reductions over weeks are unrealistic without pharmaceutical intervention. Here's a realistic timeline by approach:

A 2012 meta-analysis of niacin trials found that doses of 1,000–3,000 mg/day of extended-release niacin reduced Lp(a) by an average of 22% (Goldberg et al., Journal of Clinical Lipidology 2010; PMID: 21122682). However, niacin fell out of clinical favor after the AIM-HIGH and HPS2-THRIVE trials failed to show cardiovascular event reduction on top of statin therapy — suggesting that Lp(a) reduction alone may not be sufficient without addressing broader inflammatory risk.

The practical takeaway: give any lifestyle or supplement intervention at least 12 weeks before rechecking Lp(a), and retest under consistent conditions (fasting, similar time of day).

---

How Can I Lower ApoB?

Although ApoB and Lp(a) are distinct markers, they share important biology: every Lp(a) particle contains one ApoB-100 molecule. Elevated ApoB is an independent predictor of cardiovascular disease — arguably a better one than LDL-C — and many patients with elevated Lp(a) also have elevated total ApoB driven by LDL and VLDL particles.

Reducing ApoB comprehensively means targeting all atherogenic particle types, not just Lp(a). Evidence-supported strategies include:

• Statins: Reduce ApoB by 30–50% by upregulating LDL receptor expression (primarily reduces LDL-derived ApoB)
• PCSK9 inhibitors: Reduce ApoB by 40–55% and have the added benefit of modestly reducing Lp(a)
• Omega-3 fatty acids (EPA-dominant): Icosapentaenoic acid (EPA) at 4g/day (as in the REDUCE-IT trial design) reduced cardiovascular events significantly; EPA also reduces VLDL-ApoB secretion
• Dietary pattern: A Mediterranean-style diet rich in fiber, olive oil, and fish reduces non-HDL-C and ApoB meaningfully over 3–6 months
• Berberine: Emerging evidence suggests berberine activates AMPK and reduces hepatic ApoB secretion, though large RCTs are still limited

Tracking ApoB alongside Lp(a) gives a far more complete picture of cardiovascular particle burden than LDL-C alone. If you're asking "how can I lower Lp(a)?" without also measuring ApoB, you're missing half the story. Learn more about reading cardiovascular lab markers alongside ApoB.

---

How Can I Lower CRP?

High-sensitivity C-reactive protein (hsCRP) is a key inflammatory biomarker that amplifies cardiovascular risk in the presence of elevated Lp(a). Lp(a) carries oxidized phospholipids (OxPL) that trigger endothelial inflammation — and hsCRP is downstream of that process. This means that even if you can't fully normalize your Lp(a) genetically, reducing systemic inflammation measurably reduces your total cardiovascular risk.

Evidence-backed strategies to lower hsCRP:

1. Omega-3 fatty acids (EPA + DHA, ≥ 2g/day): A meta-analysis of 68 trials found omega-3 supplementation significantly reduced CRP, IL-6, and TNF-α (Calder et al., Annals of Nutrition & Metabolism 2017; PMID: 28490511)
2. Physical activity: Even moderate aerobic exercise (150 min/week) reduces hsCRP by 15–25% over 12 weeks
3. Weight loss: Each 1 kg of fat mass lost reduces hsCRP by approximately 1.5% in overweight individuals
4. Magnesium: Magnesium deficiency is associated with elevated NF-κB signaling and higher CRP; repletion reduces inflammatory markers
5. Curcumin: A 2014 RCT in 117 patients with metabolic syndrome found curcumin supplementation significantly reduced hsCRP compared to placebo (Panahi et al., Phytotherapy Research 2014; PMID: 24272602)
6. Low-glycemic diet: Refined carbohydrate restriction reliably lowers fasting insulin and CRP within 4–8 weeks

If your hsCRP is above 3 mg/L alongside elevated Lp(a), that combination is a red flag that warrants a conversation with a cardiologist about aggressive primary prevention. Targeting inflammation is not a substitute for addressing Lp(a) itself — it's a complementary strategy.

---

How Can I Lower ESR?

Erythrocyte sedimentation rate (ESR) is a less specific but still clinically useful inflammatory marker — often elevated in chronic inflammation, autoimmune disease, or infection. While ESR is not a primary cardiovascular risk marker the way hsCRP or ApoB are, persistently elevated ESR (above 20 mm/hr in men, 30 mm/hr in women) alongside elevated Lp(a) can signal chronic systemic inflammation that compounds atherogenic risk.

Strategies that lower ESR overlap significantly with CRP-lowering approaches:

• Treat underlying infections or autoimmune conditions (the most important step)
• Anti-inflammatory dietary patterns (Mediterranean, whole food)
• Omega-3 supplementation
• Adequate sleep (chronic sleep deprivation elevates both ESR and CRP)
• Vitamin D repletion: Low 25-OH vitamin D is associated with elevated ESR in multiple cohort studies; correcting deficiency to ≥ 40 ng/mL often produces a gradual reduction in both markers

If ESR is persistently elevated with no obvious cause, that warrants a full inflammatory workup (ANA, anti-dsDNA, rheumatoid factor, ferritin) before attributing it purely to cardiovascular risk. ESR is a signal, not a standalone diagnosis.

---

What This Means for Your Formula

Because Lp(a) is primarily genetically driven, the supplement strategy here is less about directly dropping Lp(a) numbers and more about reducing the total inflammatory and oxidative burden that makes elevated Lp(a) dangerous. Here's how Ones approaches this:

Omega-3 (EPA/DHA): Ones includes pharmaceutical-grade omega-3 at clinically meaningful doses targeting the EPA-to-DHA ratios studied in cardiovascular trials. EPA specifically reduces VLDL triglyceride output and oxidized phospholipid burden — both directly relevant to Lp(a)'s mechanism of harm. This is one of the few supplements with direct (if modest) evidence on Lp(a) itself.

Vitamin D3 + K2 (MK-7): Ones pairs D3 with MK-7 to support endothelial function and reduce arterial calcification risk — a key concern for patients with elevated Lp(a), who have higher rates of aortic valve calcification. Vitamin D deficiency independently elevates inflammatory markers like CRP and ESR.

CoQ10/Ubiquinol (200mg): Lp(a) contributes to mitochondrial oxidative stress in arterial endothelium. Ubiquinol, the reduced form of CoQ10, supports mitochondrial electron transport and reduces LDL oxidation — one mechanism by which Lp(a) particles become more dangerous is through oxidized lipid cargo, and CoQ10 addresses that oxidative pathway.

When you upload your lab results to Ones, the AI identifies elevated Lp(a) alongside your broader lipid panel, inflammatory markers, and wearable data — then calibrates a formula that addresses your full cardiovascular risk profile, not just a single number. For a deeper look at how omega-3 dosing affects cardiovascular markers, or to understand the connection between vitamin D and heart health, those resources add useful context to your plan.

---

Key Takeaways

• Lp(a) is 70–90% genetically determined; realistic lifestyle reductions are 5–25% at best without pharmaceutical intervention
• PCSK9 inhibitors currently offer the best-validated pharmacologic Lp(a) reduction (20–30%); RNA-targeted therapies in trials show 65–80% reductions
• Allow at least 12 weeks to assess any intervention's effect on Lp(a) before rechecking
• ApoB should be tracked alongside Lp(a) — both are independent cardiovascular risk drivers and often co-elevated
• Lowering hsCRP and ESR through omega-3s, anti-inflammatory diet, vitamin D repletion, and exercise reduces the total inflammatory context that makes elevated Lp(a) dangerous
• Supplement strategies (omega-3, ubiquinol, vitamin D3+K2) address the oxidative and inflammatory mechanisms of Lp(a) harm, even when the Lp(a) number itself can't be dramatically changed
• Always consult a cardiologist or lipidologist if your Lp(a) exceeds 125 nmol/L — this is a specialized risk factor requiring personalized clinical judgment